CorVel Co. (NASDAQ:CRVL – Get Free Report) Director Jeffrey J. Michael sold 10,477 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $116.45, for a total transaction of $1,220,046.65. Following the completion of the transaction, the director now owns 568,310 shares in the company, valued at $66,179,699.50. This represents a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
CorVel Stock Performance
Shares of NASDAQ:CRVL opened at $106.17 on Wednesday. CorVel Co. has a 52 week low of $76.20 and a 52 week high of $128.61. The company has a market capitalization of $5.45 billion, a PE ratio of 62.45 and a beta of 1.06. The company has a 50 day moving average price of $112.55 and a two-hundred day moving average price of $114.20.
CorVel (NASDAQ:CRVL – Get Free Report) last issued its earnings results on Tuesday, February 4th. The business services provider reported $0.46 EPS for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.
Institutional Investors Weigh In On CorVel
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of CorVel from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th.
View Our Latest Analysis on CorVel
CorVel Company Profile
CorVel Corporation provides workers’ compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Featured Articles
- Five stocks we like better than CorVel
- Health Care Stocks Explained: Why You Might Want to Invest
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Conference Calls and Individual Investors
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.